Skip to main
RLAY

RLAY Stock Forecast & Price Target

RLAY Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 83%
Buy 17%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Relay Therapeutics Inc. is positioned favorably in the clinical-stage precision medicine sector due to its innovative Dynamo platform, which effectively addresses challenging drug-protein targets and is set to enhance the development of promising oncology and genetic disease treatments. The company’s product candidate, RLY-2608, is anticipated to gain significant market share as its clinical data suggests superior efficacy and a better tolerability profile compared to existing treatments such as capivasertib, indicating it may facilitate longer duration therapies and broader market expansions. This potential for rapid market adoption, in conjunction with the successful performance of capivasertib in exceeding sales expectations and expanding its market to approximately $700 million, underscores a highly optimistic outlook for Relay Therapeutics’s stock.

Bears say

Relay Therapeutics Inc. is experiencing a significant decline in expected median progression-free survival (mPFS) from 24 months to just 5 months, which may adversely affect patient outcomes and market acceptance of its therapies. Furthermore, safety concerns associated with inavolisib have negatively impacted its commercial launch, yielding disappointing results that fall short of expectations for a first-line product. The company is also facing increased competition in its market, exemplified by the reported decline in sales for Piqray, highlighting broader challenges within its commercial landscape.

RLAY has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 83% of analysts recommend a Strong Buy, 17% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Relay Therapeutics, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Relay Therapeutics, Inc. (RLAY) Forecast

Analysts have given RLAY a Strong Buy based on their latest research and market trends.

According to 6 analysts, RLAY has a Strong Buy consensus rating as of Jan 2, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Relay Therapeutics, Inc. (RLAY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.